No RNA monitoring; switch 6 Switch immediately after Wait 6 months after failure months after confirmation of failure confirmation of failure confirmation to switch (comparison) Years Post ART Initiation First-line NVP First-line LPV/r First-line NVP First-line LPV/r First-line NVP First-line LPV/r 6 Months 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 12 Months 22.80 % 8.40% 0.01% 0.01% 0.00% 0.00% 24 Months 22.84% 9.46% 21.23% 7.89% 4.33% 1.93% 36 Months 28.24% 16.83% 21.59% 9.22% 6.32% 2.61% 48 Months 32.76% 23.02% 26.86% 16.33% 10.07% 3.96% 60 Months 37.16% 28.86% 32.36% 23.46% 14.15% 5.64% nevirapine; lopinavir/ritonavir; antiretroviral therapy; life expectancy (years) NVP: LPV/r: ART: LE: a. Results are shown for a cohort of children presenting to care at 12 months of age. Proportions are of the original presenting cohort; children who die or are lost to follow-up are included in the denominator of each calculation. When limited to children in care and on ART, proportions on second-line ART will be higher than those shown here.
Years Post ART Initiation Switch immediately after confirmation of failure Wait 6 months after failure confirmation to switch No RNA monitoring; switch 6 months after confirmation of failure (comparison) First-line NVP First-line LPV/r First-line NVP First-line LPV/r First-line NVP First-line LPV/r 6 Months 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 12 Months 22.80 % 8.40% 0.01% 0.01% 0.00% 0.00% 24 Months 22.84% 9.46% 21.23% 7.89% 4.33% 1.93% 36 Months 28.24% 16.83% 21.59% 9.22% 6.32% 2.61% 48 Months 32.76% 23.02% 26.86% 16.33% 10.07% 3.96% 60 Months 37.16% 28.86% 32.36% 23.46% 14.15% 5.64% NVP: nevirapine; LPV/r: lopinavir/ritonavir; ART: antiretroviral therapy; LE: life expectancy (years) a. Results are shown for a cohort of children presenting to care at 12 months of age. Proportions are of the original presenting cohort; children who die or are lost to follow-up are included in the denominator of each calculation. When limited to children in care and on ART, proportions on second-line ART will be higher than those shown here.
QAD_2015_03_26_CIARANELLO_QAD-14-00628_SDC1.docx